TM
BCRX icon

Torren Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Torren Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-111
Closed -$866 – 1044
2025
Q4 		$866 Buy
+111
New +$802 ﹤0.01% 1224

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Torren Management's BCRX Position: Q1 2026 in Review

Torren Management sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2026, closing a stake of 111 shares — an estimated $866 sold.

Torren Management first reported a position in BCRX in Q4 2025 and held it in 1 quarter. The position peaked at $866 in Q4 2025. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Torren Management reported no remaining BioCryst Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Torren Management sold 111 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $866.
  • Torren Management first reported a position in BioCryst Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Torren Management's BioCryst Pharmaceuticals position peaked at $866 in Q4 2025.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.